Literature DB >> 6891654

High incidence of pericardial effusion in non-Hodgkin's lymphoma: usefulness of echocardiography.

G C Acquatella, E T Roura, A J Maury, R O Stern, H Acquatella.   

Abstract

In a consecutive group of patients with non-Hodgkin's lymphoma a prospective study was designed to detect pericardial and myocardial abnormalities at presentation for initial clinical staging. Thirty-two patients, ranging from 15 to 65 (mean, 46) years of age, were studied. Twenty-six (81%) were in Stages III and IV. Echocardiographic examination revealed that 17 patients (53%) had pericardial effusion (PE). Four subjects with lymphoblastic lymphoma and extensive mediastinal involvement had clinical and echographic signs of cardiac-tamponade. In 5 cases, pericardiocentesis was performed; abnormal lymphoblasts were demonstrated in 4. In one of these, the histological diagnosis of lymphoma was performed from analysis of the PE. The follow-up ranged from 3 to 32 (mean, 12.3) months. There was no difference in the survival rates whether or not PE was present: 70 and 68% respectively at 1 yr. No patient required intracavitary chemotherapy or surgery. We conclude that PE in advanced non-Hodgkin's lymphoma with large mediastinal masses is frequent. Once tamponade is treated, the presence of PE has no adverse effect on survival at 1 yr.

Entities:  

Mesh:

Year:  1982        PMID: 6891654     DOI: 10.1016/0277-5379(82)90094-3

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  2 in total

Review 1.  Managing malignant pericardial effusion.

Authors:  A C Buzaid; H S Garewal; B R Greenberg
Journal:  West J Med       Date:  1989-02

2.  Lateral position prevents respiratory occlusion during surgical procedure under general anesthesia in the patient of huge anterior mediastinal lymphoblastic lymphoma.

Authors:  Yasunori Cho; Satoru Suzuki; Masakazu Yokoi; Muneaki Shimada; Saburo Kuwabara; Akira Murayama
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2004-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.